TELA Bio, Inc.
TELA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.18 | -0.14 | 0.07 |
| FCF Yield | 0.00% | -9.11% | -17.67% | -6.44% |
| EV / EBITDA | 0.00 | -11.26 | -5.57 | -14.10 |
| Quality | ||||
| ROIC | 0.00% | -17.41% | -17.03% | -11.41% |
| Gross Margin | 67.52% | 69.84% | 67.56% | 63.58% |
| Cash Conversion Ratio | 0.66 | 0.80 | 0.86 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.23% | 15.27% | 16.45% | 18.72% |
| Free Cash Flow Growth | 0.00% | 17.81% | -25.17% | 14.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.82 | 0.11 | 1.41 |
| Interest Coverage | 6.29 | -7.64 | -8.59 | -6.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.54 | 0.44 | 0.50 |
| Cash Conversion Cycle | 0.00 | 198.13 | 194.08 | 200.38 |